Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback